Skip to main content

Merck & Co., Inc. (MRK)

New York Stock Exchange Healthcare Drug Manufacturers - GeneralView data quality →
56.8Fair

ValueMarkers Composite Index

Top 65%#15,627 of 44,714
Undervalued

28% below intrinsic value ($158)

UndervaluedFair ValueOvervalued
Piotroski
5/9
Neutral
Beneish
-2.45
Low Risk
Altman
4.01
Safe
DCF Value
$158
Undervalued
ROIC
20.8%
Strong
P/E
16.4
Fair
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Merck & Co., Inc. (MRK) — VMCI valuation read

Merck & Co., Inc. (MRK) carries a VMCI composite of 57/100, 7 points above the Healthcare sector median of 50. Among mid-cap names, that gap places MRK in the top third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The MRK insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads MRK trades at 16.0x earnings, 11% below the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 14.0% sits 4.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of 2.3x is the rate-sensitivity line to watch, the line to track on Merck & Co., Inc.'s next 10-Q.

MRK rose 2.3% over the trailing 7 days, with a -4.4% read on a 30-day basis.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

CEO: Robert Davis73,000 employeesUSwww.merck.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in MRK’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.